The renin-angiotensin system and insulin resistance

Current Diabetes Reports

Volumn 7, Issue 1, 2007, Pages 34-42

  Liu, Zhenqi ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN 1; IRBESARTAN; LISINOPRIL; LOSARTAN; METFORMIN; NATEGLINIDE; PERINDOPRIL; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERKALEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY DISEASE; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VASOCONSTRICTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 33847408486     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0007-5     Document Type: Review

References (62)

1. Lerman A, Zeiher AM: Endothelial function: cardiac events. Circulation 2005, 111:363-368.
2. Meigs JB, Hu FB, Rifai N, et al.: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291:1978-1986.
3. Carey RM, Siragy HM: Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003, 24:261-271.
4. Carey RM: Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 2005, 45:840-844.
5. Paul M, Poyan Mehr A, Kreutz R: Physiology of local reninangiotensin systems. Physiol Rev 2006, 86:747-803.
6. Kamide K, Rakugi H, Nagai M, et al.: Insulin-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth. J Hypertens 2004, 22:121-127.
7. Lim HS, MacFadyen RJ, Lip GYH: Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med 2004, 164:1737-1748.
8. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed] N Engl J Med 1991, 325:293-302.
9. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [no authors listed]. N Engl J Med 1992, 327:685-691.
10. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. Lancet 2000, 355:253-259.
11. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
12. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
13. Wing LMH, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583-592.
14. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
15. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators [no authors listed]. Lancet 2003, 362:782-788.
16. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. PROGRESS Collaborative Group [no authors listed]. Lancet 2001, 358:1033-1041.
17. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension [no authors listed]. Circulation 2005, 112:1339-1346.
18. Demers C, McMurray JJV, Swedberg K, et al.: Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 2005, 294:1794-1798.
19. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators [no authors listed]. Lancet 1993, 342:821-828.
20. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
21. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. The PEACE Trial Investigators [no authors listed]. N Engl J Med 2004, 351:2058-2068.
22. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
23. Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
24. Lithell H, Hansson L, Skoog I, et al.: The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
25. Schiffrin EL, Park JB, Intengan HD, et al.: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000, 101:1653-1659.
26. Klingbeil AU, John S, Schneider MP, et al.: Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003, 16:123-128.
27. Hillege HL, Fidler V, Diercks GFH, et al.: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106:1777-1782.
28. Schmieder RE: Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J Hypertens 2006, 24:S31-S35.
29. Barnett AH, Bain SC, Bouter P, et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-1961.
30. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
31. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
32. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
33. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440-1444.
34. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
35. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124.
36. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002, 288:2981-2997.
37. Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003, 21:1563-1574.
38. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. N Engl J Med 2000, 342:145-153.
39. Yusuf S, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes, JAMA 2001, 286:1882-1885.
40. Lindholm LH, Ibsen H, Borch-Johnsen K, et al.: Risk of new-onset diabetes in the Losartau Intervention For Endpoint reduction in hypertension study. J Hypertens 2002, 20:1879-1886.
41. Vermes E, Ducharme A, Bourassa MG, et al.: Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the studies of left ventricular dysfunction (SOLVD). Circulation 2003, 107:1291-1296.
42. Niklason A, Hedner T, Niskanen L, et al.: Development of diabetes is retarded by ACE inhibition in hypertensive patients - a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004, 22:645-652.
43. Scheen AJ: Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004, 64:2537-2565.
44. Taniguchi CM, Emanuelli B, Kahn CR: Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006, 7:85-96.
45. Kim JA, Montagnani M, Koh KK, et al.: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
46. Li G, Barrett EJ, Wang H, et al.: Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology 2005, 146:4690-4696.
47. Baines CP, Wang L, Cohen MV, et al.: Myocardial protection by insulin is dependent on phosphatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Res Cardiol 1999, 94:188-198.
48. Jonassen AK, Sack MN, Mjos OD, et al.: Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70 S6 kinase cell-survival signaling. Circ Res 2001, 89:1191-1198.
49. Wallis MG, Wheatley CM, Rattigan S, et al.: Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes 2002, 51:3492-3498.
50. Clerk LH, Vincent MA, Jahn LA, et al.: Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes 2006, 55:1436-1442.
51. Eringa EC, Stehouwer CDA, Merlijn T, et al.: Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc Res 2002, 56:464-471.
52. Eringa EC, Stehouwer CDA, van Nieuw Amerongen GP, et al.: Vasoconstrictor effects of insulin in skelet al muscle arterioles are mediated by ERK1/2 activation in endothelium. Am J Physiol Heart Circ Physiol 2004, 287:H2043-H2048.
53. Prasad A, Quyyumi AA: Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004, 110:1507-1512.
54. Velloso LA, Folli F, Sun XJ, et al.: Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A 1996, 93:12490-12495.
55. Folli F, Kahn CR, Hansen H, et al.: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997, 100:2158-2169.
56. Andreozzi F, Laratta E, Sciacqua A, et al.: Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 2004, 94:1211-1218.
57. Shinozaki K, Ayajiki K, Nishio Y, et al.: Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 2004, 43:255-262.
58. Leri A, Claudio PP, Li Q, et al.: Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bd-2-to-Bax protein ratio in the cell. J Clin Invest 1998, 101:1326-1342.
59. Kamide K, Hori MT, Zhu JH, et al.: Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 1998, 32:482-487.
60. Horiuchi M, Akishita M, Dzau VJ: Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999, 33:613-621.
61. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
62. Zhang L, Cheng J, Ma Y, et al.: Dual pathways for nuclear factor kappaB activation by angiotensin II in vascular smooth muscle: phosphorylation of p65 by IkappaB kinase and ribosomal kinase. Circ Res 2005, 97:975-982.